These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 36293076)

  • 41. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
    Yusuf AA; Howell BL; Powers CA; St Peter WL
    Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact of accessibility to non-calcium-based phosphate binders and calcimimetics on mineral outcomes in patients receiving maintenance hemodialysis: A 10-year retrospective analysis of real-world data.
    Disthabanchong S; Kasempin P; Srisuwarn P; Chansomboon P; Buachum N
    PLoS One; 2024; 19(5):e0304649. PubMed ID: 38820324
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Mineral and bone disorder in chronic kidney disease : Critical appraisal of pharmacotherapy].
    Brunkhorst R
    Internist (Berl); 2014 Mar; 55(3):334-9. PubMed ID: 24522558
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Secondary hyperparathyroidism in chronic kidney disease: pathomechanism and current treatment possibilities.
    Rodzoń-Norwicz M; Norwicz S; Sowa-Kućma M; Gala-Błądzińska A
    Endokrynol Pol; 2023; 74(5):490-498. PubMed ID: 37902013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
    Palmer SC; Teixeira-Pinto A; Saglimbene V; Craig JC; Macaskill P; Tonelli M; de Berardis G; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2015 Dec; 66(6):962-71. PubMed ID: 26003472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Changing Spectrum of Mineral Bone Disorder in Chronic kidney disease stage 3 to 5 D and Its Associated Factors, A Prospective Cross-Sectional Study from Tertiary Care Hospital in Northern India.
    Sethi S; Sethi N; Sandhu JS; Makkar V; Kaur S; Sohal PM; Mehta S
    Iran J Kidney Dis; 2021 May; 15(3):199-205. PubMed ID: 33994379
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phosphorus and other aspects of CKD-MBD in the conservative management of chronic kidney disease.
    Shah A
    Panminerva Med; 2017 Jun; 59(2):124-132. PubMed ID: 28290186
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?
    Martin KJ; González EA
    Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CKD-MBD: impact on management of kidney disease.
    Ogata H; Koiwa F; Kinugasa E; Akizawa T
    Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.
    Bacchetta J; Bernardor J; Garnier C; Naud C; Ranchin B
    Calcif Tissue Int; 2021 Jan; 108(1):116-127. PubMed ID: 31996964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Laboratory abnormalities in CKD-MBD: markers, predictors, or mediators of disease?
    Evenepoel P; Rodriguez M; Ketteler M
    Semin Nephrol; 2014 Mar; 34(2):151-63. PubMed ID: 24780470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Calcium, phosphate and parathyroid metabolism in kidney transplanted patients.
    Ambrus C; Molnar MZ; Czira ME; Rosivall L; Kiss I; Remport A; Szathmari M; Mucsi I
    Int Urol Nephrol; 2009 Dec; 41(4):1029-38. PubMed ID: 19701690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current therapeutic approach of chronic kidney disease-mineral and bone disorder.
    Zaimi M; Grapsa E
    Ther Apher Dial; 2024 Oct; 28(5):671-689. PubMed ID: 38898685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in kano, northwest nigeria.
    Abdu A; Abdu A; Arogundade FA
    Ann Afr Med; 2019; 18(4):191-195. PubMed ID: 31823953
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Secondary hyperparathyroidism among Nigerians with chronic kidney disease.
    Gimba ZM; Abene EE; Agbaji OOO; Agaba EI
    Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Importance of Phosphate Control in Chronic Kidney Disease.
    Tsuchiya K; Akihisa T
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.